

CASP4 RABBIT PAB

货号: S221525

产品全名: CASP4 兔多抗

基因符号 TX; Mih1; ICH-2; Mih1/TX; ICEREL-II; ICE(rel)II

UNIPROT ID: P49662 (Gene Accession - NP_001216)

背景: This gene encodes a protein that is a member of the cysteine-aspartic acid protease (caspase) family. Sequential activation of caspases plays a central role in the execution-phase of cell apoptosis. Caspases exist as inactive proenzymes composed of a prodomain and a large and small protease subunit. Activation of caspases requires proteolytic processing at conserved internal aspartic residues to generate a heterodimeric enzyme consisting of the large and small subunits. This caspase is able to cleave and activate its own precursor protein, as well as caspase 1 precursor. When overexpressed, this gene induces cell apoptosis. Alternative splicing results in transcript variants encoding distinct isoforms.

抗原: Synthetic peptide of human CASP4

经过测试的应用: ELISA, IHC

推荐稀释比: IHC: 25-100; ELISA: 5000-10000

种属反应性: Rabbit

克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG


纯化: Antigen affinity purification

种属反应性: Human


成分: PBS (without Mg²⁺ and Ca²⁺), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Cancer


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human liver cancer tissue using 221525(CASP4 Antibody) at a dilution of 1/25(Cytoplasm and Cell membrane).



In comparison with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with the synthetic peptide and then with 221525(Anti-CASP4 Antibody) at dilution 1/25.



The image on the left is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using 221525(Anti-CASP4 Antibody) at a dilution of 1/25.



In comparison with the IHC on the left, the same paraffin-embedded Human thyroid cancer tissue is first treated with synthetic peptide and then with D260160(Anti-CASP4 Antibody) at dilution 1/25.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010
